Lucia B.
- Country
- Italy
- Department
- Department of Oncology
Research Overview
- A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
- Phase 2 Multicenter Study of Pembrolizumab and Lenvatinib in Patients with Vulvar Cancer
Data & Insights
Has run more than one trial at 2 of 79 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in early breast cancer treatment, with particular emphasis on HER2-positive and hormone receptor-positive breast cancers.
- Targeted Therapy Development
- Neoadjuvant Treatment Approaches
- Personalized Medicine Strategies
A key focus lies in investigating novel therapeutic combinations involving endocrine therapy and targeted biological agents.
Molecular Oncology
The investigator focuses on understanding molecular pathways in breast cancer, particularly the PIK3CA mutation pathway and its role in treatment response.
- Biomarker Research
- Pathway Inhibition Studies
- Treatment Response Assessment
Research interests include the development of targeted therapeutic approaches for specific molecular subtypes of breast cancer.
Clinical Innovation
The investigator explores combination therapy strategies in breast cancer treatment, focusing on integrating multiple targeted agents.
- Treatment Response Evaluation
- Pathological Response Assessment
- Novel Treatment Combinations
Expertise includes evaluating pathological complete response as a measure of treatment effectiveness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.